Department of Natural Science and Health, Faculty of Arts and Sciences, Middle East University, P.O. Box 90-481, Jdeidet El Metn 1202-2040, Lebanon.
Department of Biochemistry and Molecular Biology, Indiana University School of Medicine-South Bend, South Bend, IN 46617, USA.
Int J Mol Sci. 2023 Jan 20;24(3):2100. doi: 10.3390/ijms24032100.
The cancer secretome comprises factors secreted by tumors, including cytokines, growth factors, proteins from the extracellular matrix (ECM), proteases and protease inhibitors, membrane and extracellular vesicle proteins, peptide hormones, and metabolic proteins. Secreted proteins provide an avenue for communication with other tumor cells and stromal cells, and these in turn promote tumor growth and progression. Breast cancer is the most commonly diagnosed cancer in women in the US and worldwide. Triple-negative breast cancer (TNBC) is characterized by its aggressiveness and its lack of expression of the estrogen receptor (ER), progesterone receptor (PR), and HER2, making it unable to be treated with therapies targeting these protein markers, and leaving patients to rely on standard chemotherapy. In order to develop more effective therapies against TNBC, researchers are searching for targetable molecules specific to TNBC. Proteins in the TNBC secretome are involved in wide-ranging cancer-promoting processes, including tumor growth, angiogenesis, inflammation, the EMT, drug resistance, invasion, and development of the premetastatic niche. In this review, we catalog the currently known proteins in the secretome of TNBC tumors and correlate these secreted molecules with potential therapeutic opportunities to facilitate translational research.
癌症分泌组包括肿瘤分泌的因子,包括细胞因子、生长因子、细胞外基质 (ECM) 中的蛋白质、蛋白酶和蛋白酶抑制剂、膜和细胞外囊泡蛋白、肽激素和代谢蛋白。分泌蛋白为与其他肿瘤细胞和基质细胞进行交流提供了途径,而这些细胞反过来又促进了肿瘤的生长和进展。乳腺癌是美国和全球女性最常见的癌症。三阴性乳腺癌 (TNBC) 的特点是侵袭性强,缺乏雌激素受体 (ER)、孕激素受体 (PR) 和 HER2 的表达,使其无法用针对这些蛋白标志物的治疗方法进行治疗,使患者只能依赖标准化疗。为了开发针对 TNBC 的更有效疗法,研究人员正在寻找针对 TNBC 的可靶向分子。TNBC 分泌组中的蛋白质参与广泛的促进癌症的过程,包括肿瘤生长、血管生成、炎症、EMT、耐药性、侵袭和前转移龛的形成。在这篇综述中,我们列出了 TNBC 肿瘤分泌组中目前已知的蛋白质,并将这些分泌分子与潜在的治疗机会相关联,以促进转化研究。